Four Urology Times Clinical Forums show that ARPI safety, drug interactions, and cognitive effects, not efficacy alone, guide mCSPC therapy selection.
From Trial to Treatment: Applying the Latest Evidence in mCSPC Management
Clinicians across four cities weigh ARASEC and ARANOTE trial data, drug interactions, and access barriers in mCSPC treatment decisions.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
Patient Selection and Partnership in Prostate Radiotherapy Spacing
3
Jonathan Harper, MD, on the importance of fluid intake for reducing stone recurrence
4
Cameron Jones, MD, discusses patient selection for Aquablation
5